These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 1493934)
1. The concept of dose intensification in the treatment of neoplastic disease. Wandl UB; Niederle N Infection; 1992; 20 Suppl 2():S107-10. PubMed ID: 1493934 [TBL] [Abstract][Full Text] [Related]
2. The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas. Liem GS; Verweij J Stem Cells; 1994 Jul; 12(4):402-8. PubMed ID: 7951007 [TBL] [Abstract][Full Text] [Related]
3. Dose optimisation and intensification of cytotoxics in solid tumours supported by haematopoietic growth factors. Le Chevalier T Eur J Cancer; 1994; 30A(3):410-2. PubMed ID: 8204370 [No Abstract] [Full Text] [Related]
4. Mobilization of peripheral blood progenitor cells by hematopoietic growth factors. Chao NJ Can J Oncol; 1995 Dec; 5 Suppl 1():43-6. PubMed ID: 8853524 [TBL] [Abstract][Full Text] [Related]
5. High dose chemotherapy with haemopoietic support for breast cancer. Steward WP Eur J Cancer; 1995; 31A Suppl 7():S21-4. PubMed ID: 8562187 [No Abstract] [Full Text] [Related]
6. [Use of hematopoietic growth factors in oncology]. Delmer A; Zittoun R Bull Cancer; 1991; 78(2):115-31. PubMed ID: 2036483 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of haematopoietic growth factors: defining relevant clinical endpoints in growth factor trials. Linch DC Eur J Cancer; 1994; 30A Suppl 3():S40-3. PubMed ID: 7695958 [TBL] [Abstract][Full Text] [Related]
8. Some aspects of cancer medicine. Malpas JS J R Coll Physicians Lond; 1994; 28(2):136-142. PubMed ID: 8006866 [TBL] [Abstract][Full Text] [Related]
10. [Dose intensity in cancer chemotherapy (including high dose chemotherapy)]. Ariyoshi Y; Ogawa M Gan To Kagaku Ryoho; 1994 Dec; 21(16):2699-707. PubMed ID: 7993104 [TBL] [Abstract][Full Text] [Related]
11. The present and future of hematopoietic cytokines in clinical practice. George MJ Stem Cells; 1994; 12 Suppl 1():249-55. PubMed ID: 7696964 [TBL] [Abstract][Full Text] [Related]
13. Optimizing the management of chemotherapy-induced neutropenia. Dale DC Clin Adv Hematol Oncol; 2003 Nov; 1(11):679-84. PubMed ID: 16258470 [TBL] [Abstract][Full Text] [Related]
14. Dose-intensive therapy for small cell lung cancer. Elias AD Chest; 1995 Jun; 107(6 Suppl):261S-266S. PubMed ID: 7781403 [TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy of bladder carcinoma. Current status and trends]. Block T Urologe A; 1994 Nov; 33(6):557-67. PubMed ID: 7817457 [TBL] [Abstract][Full Text] [Related]
16. Dose optimisation and dose intensification in malignant lymphoma. Linch DC Eur J Cancer; 1994; 30A(1):122-5. PubMed ID: 8142153 [No Abstract] [Full Text] [Related]
18. [Hematopoietic growth factors in oncology and hematology. Recommendations for more cost-efficient use]. Paul C; Hast R Lakartidningen; 2000 Jun; 97(23):2862-6. PubMed ID: 10885223 [No Abstract] [Full Text] [Related]
19. Cytotoxic drugs: the search for dose response. Dodwell DJ Lancet; 1993 Mar; 341(8845):614-6. PubMed ID: 8094841 [No Abstract] [Full Text] [Related]
20. Chemotherapy dose intensity facilitated by use of lenograstim--implications for quality of life and survival. Gisselbrecht C Eur J Cancer; 1994; 30A Suppl 3():S30-3. PubMed ID: 7535070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]